| Similar Articles |
|---|
 |
BusinessWeek
April 26, 2004
Kerry Capell |
Vaccinating The World's Poor GlaxoSmithKline Biologicals is betting it can combat Third World scourges -- and still make money.   |
Bio-IT World
Dec 2005/Jan 2006
Salvatore Salamone |
Gates, Clinton Address Global Health Summit The conference brought together leaders in business, government, medicine, public philanthropic groups, and the arts to address and develop solutions to the world's heath crises. |
BusinessWeek
November 29, 2004
Kerry Capell |
"A Vaccine Every Woman Should Take" Two drug companies are closing in on shots against HPV, the leading cause of cervical cancer. Despite the obvious benefits, the vaccines may not be an easy sell: There are social and moral hurdles to overcome. |
Pharmaceutical Executive
July 3, 2007
Jill Wechsler |
Washington Report: Vaccines for Everyone New vaccines can be good business and a huge boon to public health. But the challenge is to establish prices that ensure global access, and to bring necessary medications to third-world countries. |
Pharmaceutical Executive
February 1, 2009
Joanna Breitstein |
Vaccines for All The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most. |
Pharmaceutical Executive
May 1, 2006
Pasternak et al. |
Vaccines: Market on the Rebound The vaccine business was safely inoculated against higher profits. But innovative therapies and looser government controls may spark an outbreak. Are pharmaceuticals ready for this opportunity? |
Pharmaceutical Executive
October 1, 2011 |
The Legacy of High Expectations Andrew Witty, Chairman & CEO, GlaxoSmithKline, believes the pharmaceutical industry will continue to make a significant contribution to society if it continues to improve the way it goes about its work. |
Scientific American
July 2006
JR Minkel |
Dangling a Carrot for Vaccines Drug companies do not see much of a market in treating diseases of developing nations. Michael Kremer hopes to change that with a plan that taps the profit motive. |
The Motley Fool
January 21, 2010
Brian Orelli |
The Noble Gesture That Wasn't There may be a motive behind Glaxo helping to develop malaria treatments. |
The Motley Fool
April 6, 2010
Brian Orelli |
Kill It! Double-Teaming Malaria Malaria vaccine might not make Glaxo and Crucell rich, but the life-saving and PR benefits would be welcome. |
HBS Working Knowledge
February 28, 2005
Cynthia Churchwell |
Funding R&D for Neglected Diseases Research on vaccines for diseases that primarily affect low-income countries remains minimal---the risks are too high for developers. The book Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases suggests a solution. |
Chemistry World
October 9, 2013
Phillip Broadwith |
GSK to apply for malaria vaccine approval Preliminary results from the first ever Phase III clinical trial of a malaria vaccine show that it can reduce malaria infections in vaccinated children over 18 months. |
BusinessWeek
July 25, 2005
Catherine Arnst |
O.K., Roll Up Your Sleeve New vaccines are arriving but the economics are still a challenge. |
The Motley Fool
June 26, 2008
Brian Lawler |
Gauging Glaxo's Vaccine Value Surprise! The FDA actually approves Glaxo's new combination children's vaccine without delay. |
Smithsonian
November 2005 |
35 Who Made a Difference: Bill Gates The king of software takes on his biggest challenge yet: his foundation is reshaping the landscape of deadly and debilitating diseases in the developing world. |
BusinessWeek
October 4, 2004 |
"It's a Perfect Storm" for Drugmakers Glaxo CEO Jean-Pierre Garnier answers questions about the biotech industry's hardships and how his company is improving its search for new drugs |
Salon.com
December 15, 2000
Arthur Allen |
Warming to malaria With fears mounting that global climate change may cause the dreaded disease to spread, scientists turn their attention to vaccine research... |
HBS Working Knowledge
March 1, 2004
Martha Lagace |
Injecting New Life into the Vaccine Industry Vaccines for preventable diseases save millions of lives every year, yet as an industry, the vaccine business suffers a host of ailments, the CEO of Merck & Co. contends. |
Pharmaceutical Executive
February 1, 2007
Joanna Breitstein |
Net Effect Ripley Ballou may finally win approval for a vaccine he started testing as an army physician more than 25 years ago - an advance that could mark the beginning of a whole new phase in the battle against one of the world's great killers: malaria. |
Chemistry World
July 29, 2015
Maria Burke |
Malaria vaccine approval first marred by efficacy question mark After decades of research, a malaria vaccine has finally been given the green light by a regulatory agency. But with limited efficacy and questions over the vaccine's cost, its future remains unclear. |
Chemistry World
October 17, 2012
Maria Burke |
GSK pledge on trials transparency GlaxoSmithKline has announced a series of initiatives to make clinical trial data publically available that could set a precedent in an industry not known for its transparency. |
The Motley Fool
July 13, 2006
Carrie Crockett |
2 Bills Are Better Than 1 It remains to be seen exactly how closely Gates and Clinton will work together, but the current trend toward megaphilanthropy among corporate, political, and entertainment giants can only bring a surge of desperately needed help to the global community. |
Pharmaceutical Executive
July 10, 2014
Fitzpatrick & Mohan |
Vaccines: Fire in the Cold Chain It's only recently that vaccine producers experienced the commercial returns commensurate with vaccines: long record of positive public health performance. |
BusinessWeek
October 25, 2004
John Carey |
A Booster Shot For Vaccines New technology could speed the development of vaccines and keep the medicine chest stocked. |
Chemistry World
October 26, 2015
Emma Stoye |
Malaria vaccine pilot studies recommended by WHO The World Health Organization has said the RTS,S malaria vaccine should be tested further through a series of pilot studies before it can recommend its widespread use. |
BusinessWeek
January 17, 2005
Einhorn & Kripalani |
Wanted: New Weapons Against An Old Killer Many of the new malaria medicines are in early stages of development. But with tsunami-hit countries receiving billions in aid there may finally be both the will and the means to tackle one of the world's most dangerous diseases. |
Chemistry World
May 31, 2013
Phillip Broadwith |
Japanese pharma opens compound vaults Japanese pharmaceutical companies are opening up their libraries of experimental compound as part of a new partnership program. The initiative aims to find new drugs for malaria, tuberculosis and neglected tropical diseases. |
BusinessWeek
November 18, 2010
Jason Gale |
Bill Gates' Latest Challenge: Polio Bill Gates is brokering deals with drugmakers to make cheaper vaccines available. |
BusinessWeek
August 5, 2010
Bennett & Randall |
AIDS Drugs Flow to the Third World Drugmakers, once blasted for their practices, are slashing prices and licensing AIDS drugs for free to nonprofits or local manufacturers in developing countries. |
The Motley Fool
October 17, 2005
Brian Gorman |
Chasing Down Bird Flu Sanofi and GlaxoSmithKline are emerging as the likely winners in the race to produce a bird flu vaccine. |
BusinessWeek
October 4, 2004
Kerry Capell |
Why Glaxo Can't Shake the Flu Sales are weakening as hot sellers come off-patent. But the pipeline looks healthy. And there's the rub. Just when GSK's image is at a new low, its prospects are improving. |
Pharmaceutical Executive
June 1, 2005
Seth Berkley |
Backpage: Partnering for Vaccine Victories Public-private partnerships can help engage industry in AIDS vaccine research. Pharma and biotechnology companies should respond with the expertise that only they can offer. |
The Motley Fool
July 20, 2007
Brian Lawler |
Glaxo Heats Up the Vaccine Battle GlaxoSmithKline's cervical cancer vaccine gets a positive recommendation in the EU. Sales could begin in early 2008 and will compete with Gardasil, by rival Merck. |
Pharmaceutical Executive
September 1, 2006
Kieran Hartsough |
Benchmarking AIDS Pharma is taking on the global AIDS crisis. But who has crafted the best approach? The Interfaith Center on Corporate Responsibility defines best practices and matches major companies head-to-head. Grades are posted inside. |
The Motley Fool
December 19, 2005
Brian Gorman |
Developing Drug Markets Drug companies focusing on the developing world could see major payoffs. Asia, Africa, and Australia offer very significant opportunities for investors. |
Pharmaceutical Executive
September 1, 2006
Jill Wechsler |
Washington Report: New Partnerships Pursue Old Diseases A new wave of collaborations between industry, non-profits, and government seeks affordable treatments for neglected diseases around the world. |
The Motley Fool
December 6, 2004
Brian Gorman |
Pill-Popping Nation Americans are using more prescription drugs. Unfortunately for big pharma investors, pharmaceutical companies' benefits from these trends are tempered by other factors. |
Chemistry World
November 1, 2011
Sarah Houlton |
A Shot in the Arm for Drugs for Neglected Diseases A new consortium of public and private sector partners has been launched by the World Intellectual Property Organization. Its aim is to share intellectual property that may help find drugs for malaria, tuberculosis and other neglected tropical diseases. |
The Motley Fool
April 4, 2007
Brian Lawler |
GlaxoSmithKline Gets Ready for the Vaccine Wars British pharmaceutical powerhouse GlaxoSmithKline submits a marketing application to the FDA for its HPV vaccine. Investors, take note. |
Chemistry World
July 24, 2009
Matt Wilkinson |
Pharma's shot in the arm? As swine flu cases continue to erupt around the globe, the latest financial results from pharmaceutical companies Roche and GlaxoSmithKline reveal that sales of their antiviral drugs have soared. |
The Motley Fool
December 13, 2007
Brian Orelli |
Merck's Vaccination Woes Merck announces it is recalling 1.2 million doses of a vaccine that immunizes children against Hib, which causes meningitis, pneumonia, and other serious infections. |
Chemistry World
May 16, 2013
Anthony King |
GSK partners Save the Children for Africa project Pharma giant GSK is to partner the international charity Save the Children in a five year deal, which it says aims to help save the lives of one million children. The controversial compact offers a blueprint for how businesses and non-government organizations can work together, says GSK. |
Chemistry World
April 25, 2014
Andy Extance |
$25bn-plus trade sharpens pharma giants' focus Three leading pharmaceutical firms are set to exchange business segments valued at over $25 billion, in deals affecting at least 14,000 employees. |
Chemistry World
January 29, 2015
Matthew Gunther |
Ebola vaccine shown to be safe in humans GlaxoSmithKline's experimental Ebola vaccine is capable of triggering an immune response in humans, according to a new study. |
Finance & Development
December 1, 2007 |
Is the Global Health System Broken Three points of view on how the global health system can be improved: Making Markets Work by Joe Cerrell... Finding a Unified Vision by Helen Gayle and J. Stephen Morrison... Targeting the Health MDGs by Tore Godal... |
Pharmaceutical Executive
May 1, 2006
Joanna Breitstein |
Cervical Cancer: Endagered Species Preventive care is more efficient than treating disease after the fact. Now this paradigm takes hold in cancer with new HPV vaccines. Now that the science is in order, Merck and GSK face several important challenges in conditioning the market. |
Chemistry World
April 2008
Victoria Gill |
Malaria no More? A fresh round of research funding could put an end to the killer disease. |
The Motley Fool
December 30, 2008
Brian Orelli |
A Shot in the Arm for Novartis' Pipeline The company picks up the rights to a vaccine that fights a virus. |
Scientific American
October 2007
Jeffrey D. Sachs |
Ending Malaria Deaths in Africa One of the world s worst killers can be stopped soon if we make the investment. |
Scientific American
November 2008
Jessica Wapner |
Cancer Vaccine: Looking Beyond Tumor Size Proponents see hope in changing cancer vaccines' bad reputation |
